Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Status:
Completed
Trial end date:
2013-03-17
Target enrollment:
Participant gender:
Summary
This randomized phase III trial studies temozolomide (TMZ) and radiation therapy (RT) to
compare how well they work with or without bevacizumab in treating patients with newly
diagnosed glioblastoma or gliosarcoma. Drugs used in chemotherapy, such as temozolomide, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy
x-rays to kill tumor cells. Monoclonal antibodies, such as bevacizumab, may find tumor cells
and help kill them. It is not yet known whether temozolomide and radiation therapy are more
effective when given together with or without bevacizumab in treating glioblastoma or
gliosarcoma.